Nathan Ihle, PhD Seattle Genetics

Nathan Ihle joined Seattle Genetics in 2002 and has held various leadership positions in the company. In his current role, Nathan has responsibility for CMC Project & Alliance Management as well as overseeing the CMC Strategy for the company’s product portfolio.

He led the CMC team responsible for the development and commercialization of ADCETRIS® (brentuximab vedotin). Prior to joining Seattle Genetics, Nathan served as Director of Chemistry at Celltech and at PathoGenesis. Earlier in his career, he conducted drug discovery research at Merck. Dr. Ihle is trained as a synthetic organic chemist, having earned a BA from Whitman College and a Ph.D. from Stanford University. He conducted postdoctoral research at the University of California, Berkeley.